Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 57

1.

The impact of surgically placed, intraperitoneal drainage on morbidity and mortality after pancreas resection- A systematic review & meta-analysis.

Schorn S, Nitsche U, Demir IE, Scheufele F, Tieftrunk E, Schirren R, Klauss S, Sargut M, Ceyhan GO, Friess H.

Pancreatology. 2018 Apr;18(3):334-345. doi: 10.1016/j.pan.2018.02.013. Epub 2018 Feb 23. Review.

PMID:
29534868
2.

Gut microbiota modulate T cell trafficking into human colorectal cancer.

Cremonesi E, Governa V, Garzon JFG, Mele V, Amicarella F, Muraro MG, Trella E, Galati-Fournier V, Oertli D, Däster SR, Droeser RA, Weixler B, Bolli M, Rosso R, Nitsche U, Khanna N, Egli A, Keck S, Slotta-Huspenina J, Terracciano LM, Zajac P, Spagnoli GC, Eppenberger-Castori S, Janssen KP, Borsig L, Iezzi G.

Gut. 2018 Feb 6. pii: gutjnl-2016-313498. doi: 10.1136/gutjnl-2016-313498. [Epub ahead of print]

PMID:
29437871
3.

Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and pancreatic cancer.

Prokopchuk O, Grünwald B, Nitsche U, Jäger C, Prokopchuk OL, Schubert EC, Friess H, Martignoni ME, Krüger A.

BMC Cancer. 2018 Feb 2;18(1):128. doi: 10.1186/s12885-018-4055-9.

4.

Interferon-inducible CXC-chemokines are crucial immune modulators and survival predictors in colorectal cancer.

Kistner L, Doll D, Holtorf A, Nitsche U, Janssen KP.

Oncotarget. 2017 Sep 28;8(52):89998-90012. doi: 10.18632/oncotarget.21286. eCollection 2017 Oct 27.

5.

Meta-analysis of outcomes following resection of the primary tumour in patients presenting with metastatic colorectal cancer.

Nitsche U, Stöß C, Stecher L, Wilhelm D, Friess H, Ceyhan GO.

Br J Surg. 2018 Jun;105(7):784-796. doi: 10.1002/bjs.10682. Epub 2017 Oct 31. Review.

PMID:
29088493
6.

Effect of Adjuvant Chemotherapy on Elderly Colorectal Cancer Patients: Lack of Evidence.

Nitsche U, Stöss C, Friess H.

Gastrointest Tumors. 2017 Sep;4(1-2):11-19. doi: 10.1159/000479318. Epub 2017 Aug 31. Review.

PMID:
29071260
7.

Targeting myeloid derived suppressor cells with all-trans retinoic acid is highly time-dependent in therapeutic tumor vaccination.

Heine A, Flores C, Gevensleben H, Diehl L, Heikenwalder M, Ringelhan M, Janssen KP, Nitsche U, Garbi N, Brossart P, Knolle PA, Kurts C, Höchst B.

Oncoimmunology. 2017 Jun 16;6(8):e1338995. doi: 10.1080/2162402X.2017.1338995. eCollection 2017.

8.

Expression analysis of LC3B and p62 indicates intact activated autophagy is associated with an unfavorable prognosis in colon cancer.

Niklaus M, Adams O, Berezowska S, Zlobec I, Graber F, Slotta-Huspenina J, Nitsche U, Rosenberg R, Tschan MP, Langer R.

Oncotarget. 2017 May 2;8(33):54604-54615. doi: 10.18632/oncotarget.17554. eCollection 2017 Aug 15.

9.

Intraoperative wound irrigation to prevent surgical site infection after laparotomy (IOWISI): study protocol for a randomized controlled trial.

Mueller TC, Nitsche U, Kehl V, Schirren R, Schossow B, Goess R, Friess H, Reim D; IOWISI Study Group.

Trials. 2017 Sep 4;18(1):410. doi: 10.1186/s13063-017-2154-6.

10.

Contemporary strategies to improve the outcome in locally advanced pancreatic cancer.

Schneider R, Späth C, Nitsche U, Erkan M, Kleeff J.

Minerva Chir. 2017 Oct;72(5):424-431. doi: 10.23736/S0026-4733.17.07410-7. Epub 2017 May 30. Review.

PMID:
28565894
11.

Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy?

Nitsche U, Kong B, Balmert A, Friess H, Kleeff J.

Indian J Med Paediatr Oncol. 2016 Oct-Dec;37(4):211-213. doi: 10.4103/0971-5851.195731. Review.

12.

Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing.

Schmiegel W, Scott RJ, Dooley S, Lewis W, Meldrum CJ, Pockney P, Draganic B, Smith S, Hewitt C, Philimore H, Lucas A, Shi E, Namdarian K, Chan T, Acosta D, Ping-Chang S, Tannapfel A, Reinacher-Schick A, Uhl W, Teschendorf C, Wolters H, Stern J, Viebahn R, Friess H, Janssen KP, Nitsche U, Slotta-Huspenina J, Pohl M, Vangala D, Baraniskin A, Dockhorn-Dworniczak B, Hegewisch-Becker S, Ronga P, Edelstein DL, Jones FS, Hahn S, Fox SB.

Mol Oncol. 2017 Feb;11(2):208-219. doi: 10.1002/1878-0261.12023. Epub 2017 Jan 20.

13.

IL-4 mRNA Is Downregulated in the Liver of Pancreatic Cancer Patients Suffering from Cachexia.

Prokopchuk O, Steinacker JM, Nitsche U, Otto S, Bachmann J, Schubert EC, Friess H, Martignoni ME.

Nutr Cancer. 2017 Jan;69(1):84-91. doi: 10.1080/01635581.2017.1247885. Epub 2016 Nov 29.

PMID:
27897439
14.

Periostin and tumor-stroma interactions in non-small cell lung cancer.

Nitsche U, Stangel D, Pan Z, Schlitter AM, Esposito I, Regel I, Raulefs S, Friess H, Kleeff J, Erkan M.

Oncol Lett. 2016 Nov;12(5):3804-3810. Epub 2016 Sep 14.

15.

Prognosis of mucinous and signet-ring cell colorectal cancer in a population-based cohort.

Nitsche U, Friess H, Agha A, Angele M, Eckel R, Heitland W, Jauch KW, Krenz D, Nüssler NC, Rau HG, Ruppert R, Schubert-Fritschle G, Wilhelm D, Werner J, Engel J.

J Cancer Res Clin Oncol. 2016 Nov;142(11):2357-66. doi: 10.1007/s00432-016-2224-2. Epub 2016 Aug 29.

PMID:
27573386
16.

Evidence-Based Surgical Treatments for Chronic Pancreatitis.

Kleeff J, Stöß C, Mayerle J, Stecher L, Maak M, Simon P, Nitsche U, Friess H.

Dtsch Arztebl Int. 2016 Jul 25;113(29-30):489-96. doi: 10.3238/arztebl.2016.0489. Review.

17.

What to do after R1-resection of adenocarcinomas of the esophagogastric junction?

Gertler R, Richter J, Stecher L, Nitsche U, Feith M.

J Surg Oncol. 2016 Sep;114(4):428-33. doi: 10.1002/jso.24329. Epub 2016 Jun 22.

PMID:
27333949
18.

Prognostic Impact of Modulators of G proteins in Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer.

Barbazan J, Dunkel Y, Li H, Nitsche U, Janssen KP, Messer K, Ghosh P.

Sci Rep. 2016 Feb 26;6:22112. doi: 10.1038/srep22112.

19.

Gastric Adenocarcinomas Express the Glycosphingolipid Gb3/CD77: Targeting of Gastric Cancer Cells with Shiga Toxin B-Subunit.

Geyer PE, Maak M, Nitsche U, Perl M, Novotny A, Slotta-Huspenina J, Dransart E, Holtorf A, Johannes L, Janssen KP.

Mol Cancer Ther. 2016 May;15(5):1008-17. doi: 10.1158/1535-7163.MCT-15-0633. Epub 2016 Jan 29.

20.

Right Sided Colon Cancer as a Distinct Histopathological Subtype with Reduced Prognosis.

Nitsche U, Stögbauer F, Späth C, Haller B, Wilhelm D, Friess H, Bader FG.

Dig Surg. 2016;33(2):157-63. doi: 10.1159/000443644. Epub 2016 Jan 30.

PMID:
26824772

Supplemental Content

Loading ...
Support Center